Viking Therapeutics, Inc. (LON:0VQA)

Market Cap	3.17B
Revenue (ttm)	n/a
Net Income (ttm)	-125.21M
Shares Out	n/a
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,478
Average Volume	14,454
Open	36.33
Previous Close	34.44
Day's Range	35.42 - 38.15
52-Week Range	18.93 - 91.00
Beta	n/a
RSI	67.57
Earnings Date	Jul 23, 2025

About The Duckhorn Portfolio

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 36
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VQA

Financial Performance

Financial numbers in DKK